Tamoxifen embedded in lipid bilayer improves the oncotarget of liposomal daunorubicin in vivo.
暂无分享,去创建一个
Tianfu Wang | Meifang Liu | Tianfu Wang | Qun Wang | Haisheng Peng | Ran Wang | Shilong Geng | Qun Wang | Haisheng Peng | Minghui Li | Hui Yu | Naidan Chang | J. Q. Zhang | Dan Du | Shouli Sun | Ran Wang | H. Q. Tao | Shilong Geng | Z. Y. Shen | Hui Yu | Minghui Li | T. Wang | R. Wang | Z. Shen | M. Li | Shou-li Sun | Nai-dan Chang | Q. Wang | M. Liu | H. Tao | Mei-fang Liu | Dan Du | J. Q. Zhang | N. Chang | H. Peng | S. Geng | M. Liu | D. Du | H. Yu | S. L. Sun | S. Sun | Shou-li Sun | Minghui Li | Hui Yu | Ran Wang | Qun Wang
[1] Ming-hui Li,et al. The liposomal daunorubicin plus tamoxifen: improving the stability, uptake, and biodistribution of carriers , 2012, Journal of liposome research.
[2] Yuquan Wei,et al. Therapeutic application of injectable thermosensitive hydrogel in preventing local breast cancer recurrence and improving incision wound healing in a mouse model. , 2012, Nanoscale.
[3] F. DuBru,et al. Relation among the resistance factor, kinetics of uptake, and kinetics of the P-glycoprotein-mediated efflux of doxorubicin, daunorubicin, 8-(S)-fluoroidarubicin, and idarubicin in multidrug-resistant K562 cells. , 1996, Molecular pharmacology.
[4] R. Mumper,et al. Development of idarubicin and doxorubicin solid lipid nanoparticles to overcome Pgp-mediated multiple drug resistance in leukemia. , 2009, Journal of biomedical nanotechnology.
[5] R. Scheper,et al. Breast cancer resistance protein expression and resistance to daunorubicin in blast cells from patients with acute myeloid leukaemia , 2001, British journal of haematology.
[6] Xin-Peng Zeng,et al. Nanomaterials in cancer-therapy drug delivery system. , 2013, Journal of biomedical nanotechnology.
[7] U. Persson,et al. Cost-effectiveness analysis of pegylated-liposomal doxorubicin and liposomal daunorubicin treatments in patients with Kaposi's sarcoma. , 1999, Acta oncologica.
[8] L. Gianni,et al. Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity , 2004, Pharmacological Reviews.
[9] C. Peterson,et al. Comparison of idarubicin and daunorubicin regarding intracellular uptake, induction of apoptosis, and resistance. , 2002, Cancer letters.
[10] Yaping Li,et al. Mesoporous silica nanoparticles loading doxorubicin reverse multidrug resistance: performance and mechanism. , 2011, Nanoscale.
[11] S. Veintemillas-Verdaguer,et al. Biodistribution and pharmacokinetics of uniform magnetite nanoparticles chemically modified with polyethylene glycol. , 2013, Nanoscale.
[12] N. Voelcker,et al. Fabrication of self-supporting porous silicon membranes and tuning transport properties by surface functionalization. , 2010, Nanoscale.
[13] Yan Zhang,et al. Effects of stealth liposomal daunorubicin plus tamoxifen on the breast cancer and cancer stem cells. , 2010, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.
[14] G. Szakács,et al. Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti‐cancer effects and pharmacological properties , 2009, British journal of pharmacology.
[15] R. White,et al. Biosynthesis of daunorubicin glycosides: role of epsilon-rhodomycinone , 1980, Antimicrobial Agents and Chemotherapy.
[16] Zhe-Sheng Chen,et al. Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters. , 2009, Biochemical pharmacology.
[17] Jie Meng,et al. Inhibiting metastasis of breast cancer cells in vitro using gold nanorod-siRNA delivery system. , 2011, Nanoscale.
[18] R. Kayyali,et al. Tamoxifen decreases drug efflux from liposomes: Relevance to its ability to reverse multidrug resistance in cancer cells? , 1994, FEBS letters.
[19] L. Wilkens,et al. Comparative Epidemiology of Breast Cancer Among Men and Women in the US, 1996 to 2000 , 2006, Cancer Causes & Control.
[20] Y. Barenholz,et al. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. , 1993, Biochimica et biophysica acta.
[21] I V Zhigaltsev,et al. LIPOSOMES CONTAINING DOPAMINE ENTRAPPED IN RESPONSE TO TRANSMEMBRANE AMMONIUM SULFATE GRADIENT AS CARRIER SYSTEM FOR DOPAMINE DELIVERY INTO THE BRAIN OF PARKINSONIAN MICE , 2001, Journal of liposome research.
[22] Hongzhuo Liu,et al. Efficacy and biodistribution of tocopheryl polyethylene glycol succinate noncovalent functionalized single walled nanotubes loading doxorubicin in sarcoma bearing mouse model. , 2012, Journal of biomedical nanotechnology.
[23] V. Ling,et al. Decreased P-glycoprotein in a tamoxifen-tolerant breast carcinoma model. , 1991, Anticancer research.
[24] Pengfei Rong,et al. VEGF-loaded graphene oxide as theranostics for multi-modality imaging-monitored targeting therapeutic angiogenesis of ischemic muscle. , 2013, Nanoscale.
[25] B. Leyland-Jones,et al. Sensitization to doxorubicin resistance in breast cancer cell lines by tamoxifen and megestrol acetate. , 1996, Biochemical pharmacology.
[26] A. Garnier-Suillerot,et al. Inhibition of the P-glycoprotein- and multidrug resistance protein-mediated efflux of anthracyclines and calceinacetoxymethyl ester by PAK-104P. , 2000, European journal of pharmacology.
[27] G. Goldenberg,et al. Anatagonism of the cytocidal activity and uptake of melphalan by tamoxifen in human breast cancer cells in vitro , 1985 .